FDA Approves First Twice-Yearly Antipsychotic for Schizophrenia FDA Approves First Twice-Yearly Antipsychotic for Schizophrenia

The FDA has approved a 6-month injection form of the long-acting atypical antipsychotic paliperidone palmitate (Invega Hafyera) for adults with schizophrenia.FDA Approvals
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Psychiatry News Alert Source Type: news